Background. Weight gain after antiretroviral therapy (ART) initiation is common, but its implication for mortality is unknown. We evaluated weight change in the first year after ART initiation and its association with subsequent mortality.
Human immunodeficiency virus (HIV) infection, prior to the widespread availability of combination antiretroviral therapy (ART), was dubbed "slim disease" and was characterized by weight loss and wasting. Thus, the rapidly growing prevalence of overweight and obesity among HIV-infected individuals receiving ART is a new phenomenon with unknown implications [1] [2] [3] .
On one hand, early weight gain after ART likely reflects reduced metabolic demand from viral replication, which suggests improved clinical outcome. On the other hand, overweight and obesity among individuals without HIV confer increased risk of morbidity (diabetes, cardiovascular disease, and stroke) and mortality [4] [5] [6] . Now that people are aging with HIV infection, we need to consider what constitutes an optimal weight gain after ART.
Prior studies of HIV and weight gain have primarily focused on factors associated with weight gain and are limited by small sample size and limited use of multivariable models [2, 7, 8] . To our knowledge, other studies have not considered the association between weight gain after ART and clinical outcomes including mortality in the developed setting. This analysis focuses on the implications of weight change over the first year after ART initiation for subsequent mortality and asks whether there is an optimal threshold for weight gain in this period and whether it depends upon weight at ART initiation. We also characterize factors associated with weight gain after ART initiation.
METHODS

Sample and Data Collection
Data were obtained from the Veterans Aging Cohort Study (VACS), a periodically updated prospective observational cohort identified from the US Department of Veterans Affairs (VA) national databases including >40 000 HIV-infected veterans [9] . Clinical information available includes diagnostic codes (International Classification of Diseases, Ninth Revision) for inpatient and outpatient visits, all medications dispensed from VA pharmacies, and health behaviors, including tobacco and alcohol use. Deaths were identified from the VA Vital Status file, which uses data from the Social Security Death Master File, Medicare Vital Status Files, and VA Beneficiary Identification and Records Locator Subsystem.
Eligible HIV-infected patients for this study were in VA care between 1 January 1999 and 30 September 2008 and initiated ART after 1 January 2000. We defined baseline as the date of ART initiation. Patients were determined to be ART naive using a validated algorithm (no prior history of receiving an ART medication within the VA system and not already receiving ART with a recorded HIV type 1 [HIV-1] RNA level >500 copies/mL) and had weight recorded at baseline and again 9-18 months later [10] . One pregnant woman was excluded. Body mass index (BMI), calculated as weight in kilograms divided by height in meters squared (kg/m 2 ), was calculated at baseline and 1 year later. At baseline we used the weight closest to, but no more than 90 days prior to, ART initiation. The 1-year weight was obtained in 2 ways: We used weight closest to the target date of 1 year if a value was available within ±30 days; otherwise, we interpolated from 2 weights within ±180 days of the 1-year date.
Baseline BMI was categorized as underweight (<18.5), normal weight (18.5-24.9) , overweight (25-29.9) , and obese (≥30). Our primary risk factor, change in weight, was examined after a 12-month period, with patients stratified into those who gained weight (>5-pound [2.3 kg] increase, with further subcategories), those who lost weight (>5-pound [2.3 kg] decrease), and those who stayed the same (±5 pounds [2.3 kg]). We used the VACS Index, a weighted combination of age and 8 clinical variables, including CD4 cell count, HIV RNA load, platelet count, hepatitis C serostatus, and hemoglobin, aspartate aminotransferase, alanine aminotransferase, and creatinine levels, to adjust for disease severity [11] . Patients with missing VACS Index components were excluded.
Statistical Methods
Our primary outcome was all-cause mortality. Patients were followed from 1 year after ART initiation until the earlier of 5 years, death, or 30 June 2014. We used Cox models to assess the association of weight gain with mortality, adjusting for baseline disease severity with the VACS Index, overall and stratified by baseline BMI. We explored predictors of weight gain using linear regression models including age, sex, race, BMI, the VACS Index and its components, and ART regimen. We used logistic regression models to evaluate the association of these factors with ≥10-pound (4.5 kg) weight gain. Statistical significance for all tests was defined as a 2-tailed P value <.05. Proportional hazards assumptions were met for all analyses. Analyses were performed using SAS software, version 9.2 (SAS Institute). The analytic sample included only those patients who were alive 1 year after ART initiation. Therefore, only deaths that occurred after the first year on ART were counted. The VA uses several sources to identify deaths with excellent ascertainment [12, 13] .
RESULTS
Among 20 602 HIV-infected patients entering VACS after 1 January 1999 and alive as of 1 January 2000, 10 858 newly initiated ART by 30 September 2008, of whom 6475 had HIV RNA >500 copies/mL and 5759 had an available baseline BMI. A subsequent BMI was available for 4862 patients. After excluding those with incomplete VACS Index data, the analytic sample consisted of 4311 HIV-infected patients (127 women and 4184 men), with mean age of 47.9 years (Table 1) . A majority were black (54%); only 6% were underweight at initiation, but 30% were overweight and 12% were obese. Comorbidities were common: 30% had hypertension, 10% had diabetes, and 32% were coinfected with hepatitis C. Median CD4 count at ART initiation was 187 cells/µL, and the median HIV-1 RNA level was 4.9 log copies/mL. Organ system injury was also common; 11% had a FIB-4 score consistent with liver fibrosis, and 28% had hemoglobin <12 g/dL. Median VACS Index scores were higher in underweight patients (65; interquartile range [IQR], 53-85) and normal-weight patients (50; IQR, 31-69) than in overweight (39; IQR, 24-58) and obese (36; IQR, 23-53) patients.
After 12 months of ART, median weight gain was 5.9 pounds (2.7 kg) (IQR, −2.9 to 17.0 pounds, −1.3 to 7.7 kg) and did not differ by sex (P = .55). Median weight gain differed by baseline BMI. Of underweight, normal, overweight, and obese individuals, 73%, 56%, 47%, and 44%, respectively, gained weight. Individuals who were underweight gained median of 16.0 pounds During a median of 5 years (IQR, 4.5-5.0 years) of follow-up, 708 patients died. Deaths occurred fairly uniformly in the years after ART initiation, but were somewhat more concentrated in the earlier years (year 2 = 172; year 3 = 148; year 4 = 138; year 5 = 121; and year 6 = 129). After adjustment for baseline VACS Index, weight gain after ART initiation was associated with lower mortality risk among initially underweight and normal-weight patients (Table 2) . For underweight patients, all weight gain appeared beneficial; a ≥10-pound (4.5 kg) weight gain led to a significantly reduced risk of death (hazard ratio [HR], 0.47; 95% confidence interval [CI], .25-.88; P = .02) compared with the reference group (stayed within ±5 pounds [2.3 kg] of baseline weight). In normal-weight patients, clear survival benefits were associated with at least 10 pounds (4.5 kg) of weight gain: HR, 0.56 (95% CI, .41-.78) for 10-19.9 pounds (4.5-9.0 kg); HR, 0.52 (95% CI, .35-.76) for 20-29.9 pounds, and HR, 0.42 (95% CI, .28-.62) for ≥30 pounds of weight gain. Among initially overweight and obese patients, the association with weight gain after ART initiation and mortality was unclear. Although all weight gain in obese patients was associated with point estimates consistent with increased risk of mortality, 95% CIs were wide and none were significant (P > .2 for all). Overall, weight loss after ART initiation was associated with increased mortality risk, and was statistically significant for those initially normal weight, overweight, or obese.
After combining overweight and obese groups for better precision, and using finer gradations of weight gain, we found no evidence of an inflection point ( Figure 1A and 1B) . However, the association of weight gain and mortality did appear to differ by baseline BMI. Superimposed graphs of this relationship demonstrate significantly reduced mortality risk for normalweight patients up to a 30-pound (13.6 kg) weight gain, but no significant benefit or harm associated with weight gain in overweight/obese patients ( Figure 1C) .
In multivariable analyses, factors associated with weight change included age, baseline BMI, protease inhibitor-based ART regimen, and baseline VACS Index. Each 5-point increment of VACS Index score was associated with 0.94 pounds of weight gain. Further investigation revealed that of the VACS Index components, age, CD4 cell count, and hemoglobin were strong predictors of weight gain (indicated by positive and greater magnitude of regression coefficients [β]; Table 3 ), whereas HIV-1 RNA, FIB-4 score, estimated glomerular filtration rate, and hepatitis C status were not. Baseline CD4 count <100 cells/µL was associated with an odds ratio (OR) of 2.6 (95% CI, 2.3-3.0) and hemoglobin <12 g/dL with an OR of 2.6 (95% CI, 2.2-3.0) for gaining ≥10 pounds.
DISCUSSION
Among HIV-infected veterans initiating ART from 2000 to 2008, significant weight gain over the first year was common, even among those who were overweight or obese at initiation. Whereas weight loss after ART was universally associated with increased mortality, the apparent benefits of weight gain depended upon BMI at initiation. For normal-weight patients, a minimum gain of 10-15 pounds (4.5-6.8 kg) was associated with decreased mortality. For those initially overweight or obese, weight gain after ART initiation was not significantly associated with survival. This study of weight change in the first year after ART initiation is the largest to date and appears to be the first to investigate the association between weight change following ART and subsequent mortality in the developed setting. Several studies in resource-limited settings have demonstrated a strong association between weight gain after ART and survival [14] [15] [16] .
However, we do not know whether this association persists in settings where weight at ART initiation is substantially greater. Previous studies in resource-rich settings have characterized changing weight by calendar interval among HIV-infected patients, suggesting that BMI among HIV-infected individuals on ART increasingly mirrors that observed among the general population [1] [2] [3] . Two prior studies characterized weight change in the first year after ART initiation, but these did not consider outcomes [7, 8] . All prior studies were limited to 1 or few clinical sites. Optimal weight gain after ART initiation is not a trivial question. Research outside HIV has uncovered an "obesity paradox" in complex chronic disease. Namely, an inverse association between excess adiposity (as defined by BMI) and mortality has been documented in older patients with chronic disease [17, 18] . Improved outcomes are observed in overweight and obese patients with type 2 diabetes, chronic kidney disease, chronic heart failure, chronic obstructive pulmonary disease, and coronary artery disease compared with normal-weight and underweight counterparts [17] [18] [19] [20] [21] [22] [23] [24] . Quite simply, weight may be a surrogate for health. Patients with chronic disease who are able to maintain weight may be healthier; conversely, those losing weight may suffer from underlying inflammation, increased cytokines, etc.
Distinguishing between intentional and unintentional weight loss is also important. A recent study of cardiovascular events in overweight subjects found that those who lost weight intentionally had fewer events whereas those who lost weight observationally had more events [25] . The obesity paradox may also reflect advantages to maintaining some metabolic reserve in the context of chronic disease or may be the result of unmeasured confounding.
Two prior studies support the obesity paradox among those aging with HIV. First, among a group of HIV-infected men who have sex with men, those who were overweight possessed higher CD4 cell counts and lower viral loads than those of normal weight [26] . Second, after 1 year of ART, CD4 lymphocyte recovery was greatest among patients classified as overweight [27] . Yet other studies in military cohorts have demonstrated an adverse association between excess weight and CD4 count. In one study, obese patients achieved smaller CD4 cell count and percentage increases over time [28] . Consistent with prior research, and with the obesity paradox, we found that weight loss among those with HIV infection, regardless of baseline BMI, is a strong predictor of mortality [29, 30] . The etiology of weight loss in this population is likely multifactorial and includes inadequate nutrient intake, uncontrolled HIV infection, metabolic demands of highly active ART, and opportunistic infections or malignancies [31] . Increased resting energy expenditure is observed in clinically stable HIV-infected patients and may partially account for the continued weight loss and wasting observed in HIV infection in the current era, most notably among those who fail to achieve virologic suppression [29] . There may also be a component of weight loss due to lipoatrophy and mitochondrial toxicity in patients placed on older-generation nucleoside reverse transcriptase inhibitors [32, 33] .
Uncontrolled HIV infection exerts a heavy metabolic demand upon the patient [29] . If patients do not alter their eating or activity patterns, weight gain after ART likely indicates how well viral activity has been suppressed. Our finding that severity of illness at ART initiation, as measured by the VACS Index, was strongly associated with weight gain supports this contention. As ART has become effective at suppressing HIV-1 RNA and its pathophysiologic effects on inflammation and organ system function, substantial weight gain has become common. Thus, to understand the independent benefit of weight gain, one must control for severity of illness at ART initiation. It was only after we adjusted for severity of illness at baseline that we were able to show that weight gain among those who were already overweight had no independent benefit. Our study suggests that ART initiation is an important time at which to address optimal weight gain over the subsequent year. We demonstrate that weight gain after ART is common, regardless of BMI at initiation, but its implications differ by weight status at the point of ART initiation. Current guidelines for a healthy weight in the general population advise against weight gain in normal-weight and overweight people and recommend weight loss in overweight people with a high waist circumference and risk factors for heart disease [34] . Based on our findings, weight gain appears beneficial among those who are underweight, and weight gain of approximately 10 pounds may be appropriate among those who are normal weight. Overweight and obese individuals did not show decreased mortality with weight gain, yet weight gain did not lead to increased mortality; therefore, overweight/obese patients may be counseled to engage in healthy eating and exercise habits as for all patients, without set prescriptions for weight gain or loss.
The strengths of this study include the utilization of a large cohort of patients receiving care in the VA Health System, with patients representing diverse geographical areas and medical centers, with direct measurement of ART initiation through pharmacy fill data and of BMI through medical record data. We were able to adjust for smoking. We had access to longitudinal data on weight and long-term mortality (5 years of follow-up), which allowed for comprehensive investigation of the relationship between weight gain in the year after ART initiation and subsequent mortality. A major strength of this study was the ability to adjust for disease severity using the VACS Index. The VACS Index has been validated among many cohorts as an excellent predictor of all-cause mortality among HIV-infected patients that discriminates mortality risk more effectively than indices restricted to CD4 cell count, HIV-1 RNA, and age [11, 35, 36] . Adjustment with the VACS Index at baseline allowed us to account for total burden of disease when considering mortality risk associated with weight gain.
Our study has limitations. Most importantly, the only outcome we considered was 5-year mortality. Although this is an important outcome, risk of mortality associated with overweight/obesity may increase over time, and mortality is not the only concern. Overweight/obesity increases risk of morbidity including hypertension, diabetes, and cardiovascular disease. Thus, our finding that reduced mortality risk for normal-weight patients may extend up to a 50-pound (22.7 kg) weight gain does not account for adverse health effects that may only manifest over the course of multiple years or decades. Future work will explore the long-term impact of weight gain and whether weight gain demonstrates different associations among HIV-infected and -uninfected individuals with these outcomes. This study utilized an HIV-infected cohort from the VA patient population; therefore, the results may not be generalizable to HIV-infected persons who receive care outside the VA healthcare system. Moreover, the cohort was primarily male (>97%). We did not find a significant sex difference (P = .55) and included females in our analysis; however, prior studies have found greater increases in weight gain among HIV-infected females compared with males [2, 7] . Further studies are needed among HIV-infected females. We also used BMI as a primary measure, but it does not provide information about overall fat distribution. Multiple studies have identified central adiposity as a predictor of adverse metabolic and cardiovascular outcomes independent of BMI, but our study did not differentiate between weight gain contributing to central adiposity and weight gain contributing to overall adiposity [37] [38] [39] [40] . Finally, it is important to note that our study focuses on weight change in the 12-month period following ART initiation, but it cannot be extrapolated to weight change over a more extended period. Of note, a recent study in a sample of largely Hispanic HIV-infected patients on long-term ART observed an even higher prevalence of overweight and obesity than we report, with continued weight gain over >3 years of follow-up [41] .
CONCLUSIONS
In general, weight gain in the first year after ART initiation was associated with lower mortality among initially underweight and normal-weight patients. A minimum threshold of 10-to 19.9-pound (4.5-9.0 kg) weight gain was beneficial in normalweight patients. However, there was no clear benefit to weight gain in patients who were initially overweight/obese. Providers should monitor weight gain among normal-weight and underweight patients initiating ART and examine potential reasons for failure to gain weight, including viral breakthrough, ongoing inflammation, food insecurity, drug use, and intervening comorbidities. Overweight and obese patients can be counseled to engage in healthy diet and exercise behaviors. These results provide a basis for future recommendations for weight counseling and management of HIV-infected patients initiating ART.
Notes
